TLSA Stock Summary and Trading Ideas (Tiziana Life Sciences - Common Shares | NASDAQ:TLSA)

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Tiziana Life Sciences - Common Shares trades on the NASDAQ stock market under the symbol TLSA.

As of March 24, 2026, TLSA stock price declined to $1.32 with 238,468 million shares trading.

TLSA has a beta of -0.63, meaning it tends to be less sensitive to market movements. TLSA has a correlation of 0.02 to the broad based SPY ETF.

TLSA has a market cap of $167.97 million. This is considered a Micro Cap stock.

In the last 3 years, TLSA traded as high as $2.60 and as low as $.41.

TLSA has outperformed the market in the last year with a return of +18.9%, while the SPY ETF gained +17.1%. However, in the most recent history, TLSA shares have underperformed the stock market with its stock returning -9.6% in the last 3 month period and -4.3% for the last 2 week period, while SPY has returned -4.8% and -3.4%, respectively.

TLSA support price is $1.27 and resistance is $1.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLSA shares will trade within this expected range on the day.